Introduction {#sec1-1}
============

Among main intracellular pathogens, *Mycobacterium tuberculosis* (*M. tuberculosis*) is known as the cause of a terrible infectious disease with a high mortality rate all over the world ([@ref1], [@ref2]). Tuberculosis (TB) vaccination is the most important approach to long-term control of the disease ([@ref3]). The BCG vaccine, which is a live attenuated strain of *Mycobacterium bovis*, bacillus Calmette-Guérin, is the only licensed and cost-effective vaccine but with limited and variable effects on specific individuals in prevention of active disease (0-85%) ([@ref3], [@ref4]). Therefore, the development of new vaccines is an urgent need. Currently, at least 15 TB vaccine candidates are located in various phases of clinical trials, which are classified into three main groups: 1) prime group, includes vaccines that are designed as a replacement for the current BCG vaccine, 2) prime-boost group, includes vaccines that act as boosters for the BCG vaccine and 3) immunotherapy group, includes therapeutic vaccines for effective treatment of various forms of TB disease as well as drug-resistant strains of *M. tuberculosis* ([@ref5]). However, most of these vaccines are weak immunogens, and polymer-based particles as vaccine delivery systems/adjuvants could help to attain the following goals: 1) for optimal stimulation of innate and adaptive immune systems, 2) protection of antigens from *in vivo* enzymatic degradation, 3) effective antigen targeting to antigen-presenting cells (APCs) followed by its processing by both MHC-I and II routes and then induction of CD4^+^ and CD8^+^ T cells, 4) control of inducing cell-mediated responses (Th1 or Th2) by controlling the particle size, and 5) usage as an adjuvant ([@ref6]-[@ref8]). Among various biomaterials used in the development of protein, peptide, and DNA vaccines, polymers are of great importance due to some advantages including biocompatibility with synthetic polymers, lower toxicity, biocompatibility, easy availability, and biodegrade-ability of natural polymers ([@ref8]-[@ref12]). Polymers could be cate-gorized as 1) biodegradable synthetic polymers like PLGA (poly (lactide-co-glycolide)), PLA (poly (lactide)) (both are FDA approved) ([@ref8]-[@ref11]), poly (alkyl cyanoacrylates), poly (ɛ-caprolactone), and polyphos-phates, 2) non-biodegradable synthetic polymers like polyvinylpyrrolidone, poloxamers, and poly (methyl methacrylates), and 3) natural polymers like proteins (albumin, collagen, and gelatin) and polysaccharides (chitosan/chitin and alginate) ([@ref13]). In spite of the advantages of polymeric nanoparticles (NPs), they also have some disadvantages including toxicity, non-degradability, complexity, and costly synthesis process for synthetic polymers, and more complicated structure, complexity, and expensive extraction process for natural polymers ([@ref12]).

There is two main delivery routes for vaccine administration, non-parenteral (mucosal) vaccination via intranasal, oral, vaginal, and rectal routes, and parenteral via subcutaneous and intramuscular ([@ref14]). To date, parenteral routes are the common delivery routes for TB vaccine candidates, and there is much less research on mucosal vaccination ([@ref14]). Since the respiratory mucosa is the site of TB entry, mucosal vaccination, especially the nasal route could provide good protection against TB ([@ref14]). This could be performed by the production of neutralizing anti-bodies like secretory IgA (sIgA), systemic IgG, and also activation of various CD4^+^ T cells such as Th1, Th2, and Th17, and also CD8^+^ T cells (CTLs). These could strongly stimulate both mucosal and systemic immune responses ([@ref15], [@ref16]). Th1, Th17, and CTLs mediated immunity are essential for the host defense against intracellular pathogens that enter through various mucosal surfaces, whereas CD4^+^ Th2 cells are effective against extracellular organisms ([@ref16]-[@ref18]). Antibody responses via organism opsonization and conse-quently the more efficient processing by dendritic cells (DCs) have synergistic effects on the immune system ([@ref19]). Additionally, the nasal cavity possesses other advantages such as patient compliance, better epithelium permeability, and needle-free and self-administration ([@ref14], [@ref20]). In the present review, the potential of various polymeric particles as future vaccine delivery systems/adjuvants for parenteral and mucosal immunization against TB has been investigated.

Materials and Methods {#sec1-2}
=====================

Literature search {#sec2-1}
-----------------

PubMed, Scopus, Science-Direct, and the ISI web of knowledge databases were searched to identify relevant studies up to June 25, 2016. Data from published English language articles were obtained by using the medical terms including "*M. tuberculosis* vaccine'' or "TB vaccine" and "polymeric NPs" or "polymeric microparticles" and "PLGA" and "PLA" and "poly (alkyl cyanoacrylates)" and "poly (ɛ-caprolactone)" and "polyphosphates" particles and "polyvinylpyrrolidone" and "poloxamers" and "poly (methyl methacrylates)" particles and "protein (albumin, collagen and gelatin)" particles and "polysaccharide (chitosan/chitin and alginate)" particles and "immunization" or "vaccine delivery". Finally, a supplementary search in the Google Scholar search engine and hand searching of reference lists to find the excluded articles was conducted.

Evaluation criteria {#sec2-2}
-------------------

In this systematic review, the main inclusion criteria for selection of relevant articles included: 1) published original articles written in English, 2) evaluation of various TB vaccines only based on different polymeric particles, 3) parenteral and mucosal administration of TB vaccines, and 4) assessment of different polymeric particles as adjuvants. Exclusion criteria included: 1) abstracts of articles, 2) review articles and books, 3) use of other particles as vaccine delivery systems/adjuvants, 4) assessment of vaccine delivery in other organisms, 5) duplicate studies, and 6) assessment of drug delivery in *M. tuberculosis*.

Results {#sec1-3}
=======

A total of 420 original articles were collected from different studies using systematic search in databases ([Figure 1](#F1){ref-type="fig"}). Searching was limited to polymeric particles and their roles as vaccine delivery systems/adjuvants for parenteral and mucosal immunization against TB written up to June 25, 2016. All obtained studies in the present paper were reviewed to extract the following data: 1) year of study, 2) type of polymer and adjuvant, 3) antigen(s), 4) size, zeta-potential, and preparation method of particles, 5) route of administration, 6) animal, and 7) profile of immune responses. Thirty-one selected articles were classified into three groups based on the inclusion and exclusion criteria.

![Flowchart of literature search and inclusion and exclusion criteria](IJBMS-21-116-g001){#F1}

Biodegradable synthetic polymers {#sec2-3}
--------------------------------

Among biodegradable synthetic polymers (PLGA, PLA, poly (alkyl cyanoacrylates), poly (ɛ-capro-lactone), and polyphosphates), PLGA polymers are the most widely used as TB vaccine delivery systems/adjuvants. This systematic review includes 14 studies on PLGA polymers. It is evident that PLGA (50:50) is the most frequently used polymer. All studies have used the double emulsion/solvent evaporation method (W/O/W) to prepare PLGA polymers. After administration through various routes, PLGA polymers induced high levels of antibody and Th1, Th2, and Th17 immune responses. The impact of different adjuvants such as cationic lipid, DDA (dimethyldioctadecylammonium bromide), TDB (trehalose 6, 6'-dibehenate), PEI (polyethyleneimine), TDM (trehalose dimycolate), and lipid adjuvants, such as MPL (monophosphoryl lipid A), either separately or in combination, on the particle size, zeta-potential, and profile of immune responses were reviewed ([Table 1](#T1){ref-type="table"}).

###### 

Polymeric particles as tuberculosis vaccine delivery systems

  First author (Ref)                 Year   Polymer                                     Antigen (s)                                                         Adjuvant (s)              Preparation method                                   Size                                Zeta-Potential (mV)          Route of administration              Animal                                              Profile of immune responses                                        
  ---------------------------------- ------ ------------------------------------------- ------------------------------------------------------------------- ------------------------- ---------------------------------------------------- ----------------------------------- ---------------------------- ------------------------------------ --------------------------------------------------- ----------------------------- ------------------------------------ ---------------------------------
  Rose *et al* ([@ref21])            2015   PLGA (75:25)                                MOMP                                                                DDA:TDB (CAF01)           O/W                                                  \<250 nm                            \>5                          Subcutaneous                         Female B6C3F1 mice                                  IgG1 IgG2a IgA                IFN-γ IL-17a IL-5                    NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Carletti *et al* ([@ref22])        2013   PLGA (50:50)                                Apa                                                                 TDM                       W/O/W                                                NA                                  NA                           Subcutaneous Intramuscular           Female BALB/c mice                                  NA                            NA                                   *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Shi *et al* ([@ref23])             2010   PLGA (75:25)                                TB10.4- Ag85B                                                       MDP-BSA                   Emulsion /spray-drying                               3.0µm                               −25                          Pulmonary                            NA                                                  NA                            IL-2                                 NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Bivas-Benitaa *et al* ([@ref24])   2009   PLGA (53:47)                                Rv1733c                                                             PEI                       W/O/W                                                235 - 275 nm                        +38.8 - +64.3                Intramuscular Intranasal             Female BALB/c mice                                  NA                            IFN-γ IL-12 TNF-α                    NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Kirby *et al* ([@ref25])           2008   PLGA (75:25)                                Ag85B-ESAT-6                                                        DDA:TDB (CAF01) DDA TDB   W/O/W                                                1.50± 0.13 µm                       0-15                         Subcutaneous                         Female C57BL/6j mice                                IgG1 IgG2b                    IFN-γ                                NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  de Paula *et al* ([@ref26])        2007   PLGA (50:50)                                HSP65                                                               TDM                       W/O/W                                                \<10 µm                             NA                           Intratracheal                        Female Hartley guinea pigs and Female BALB/c mice   IgG2a                         IFN-γ                                *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Lu *et al* ([@ref27])              2007   PLGA (75:25)                                rAg85B                                                              MDP TDB                   Emulsion /spray-drying                               3.4-4.3 µm                          NA                           NA                                   NA                                                  NA                            IL-2                                 NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Ha *et al* ([@ref28])              2006   PLGA (NA)                                   rAg85A ESAT-6                                                       IL-12EM AS01B alum        W/O/W                                                NA                                  NA                           Subcutaneous                         Female C57BL/6 mice                                 Total IgG IgG1 IgG2a          IFN-γ                                *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Cai *et al* ([@ref29])             2005   PLGA (50:50)                                Ag85B MPT-64 MPT-83                                                 DDA                       W/O/W                                                \<5 µm                              NA                           Intramuscular                        Female C57BL/6 mice                                 IgG                           IFN-γ                                *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Evans *et al* ([@ref30])           2004   PLGA (50:50)                                Mtb8.4                                                              MPL RC-529                Hydrophobic ion-pairing technique                    2 µm                                NA                           Intramuscular Subcutaneous           Female C57Bl/6 mice                                 IgG IgG2a                     IFN-γ                                NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Lima *et al* ([@ref31])            2003   PLGA (50:50)                                HSP65                                                               TDM                       W/O/W                                                \<5 µm                              NA                           Intramuscular                        Female BALB/c mice                                  IgG1 IgG2a                    IFN-γ IL-10 IL-4                     *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Lima *et al* ([@ref32])            2001   PLGA (50:50)                                NA                                                                  TDM                       W/O/W                                                NA                                  NA                           Intraperitoneal Intratracheal        Female BALB/c mice                                  NA                            IL-6 TNF-α IL-10 IFN-γ IL-12 IL-4    *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Dhiman *et al* ([@ref33])          1998   PLGA (50:50)                                71-kDa cell wall protein                                            FIA                       W/O/W                                                \<0.65 µm                           NA                           Intramuscular Subcutaneous           NA                                                  NA                            NA                                   *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Carpenter *et al* ([@ref34])       2005   PLA                                         ESAT-6                                                              Alum                      W/O/W                                                1.179 μm±0.07                       NA                           Pulmonary Intranasal Intramuscular   Female BALB/c mice                                  IgG                           IFN-γ IL-4                           NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Venkataprasad *et al* ([@ref35])   1999   PLA PLGA (75:25, 50:50)                     38 kDa protein                                                      NA                        W/O/W                                                PLA (3-5 µm) and PLG (0.3-0.8 µm)   NA                           Subcutaneous                         Female C57BL/10 mice                                NA                            IFN-γ IL-4                           NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Todoroff *et al* ([@ref36])        2013   Poloxamer 407                               Ag85A                                                               CpG oligonucleotide       NA                                                   27 nm                               NA                           Pulmonary (Intratracheal)            Female BALB/c mice                                  IgG, IgG1, and IgG2a          IFN-γ TNF-α IL-2 IL-17a              NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Orr *et al* ([@ref37])             2014   NA                                          ID93                                                                GLA-SE                    NA                                                   \< 120 nm                           -13                          Intramuscular                        Female C57Bl/6 mice                                 IgG1 IgG2c                    IFN-γ TNF-α IL-2                     *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Yeboah *et al* ([@ref38])          2009   Albumin                                     Dead whole cells and whole cell lysate                              NA                        Spray-drying method                                  3.52±0.13 µm 6.61±0.70 µm           -13.05 ±19.18 -40.28 ±7.86   Oral                                 Rat                                                 IgG IgA                       NA                                   NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Meerak *et al* ([@ref39])          2013   Chitosan                                    Ag85B                                                               NA                        Coacervation method                                  100--200 nm                         NA                           Subcutaneous Intranasal              Female BALB/c inbred                                total IgG IgG2a               IFN-γ IL-2 IL-4                      NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Feng *et al* ([@ref40])            2013   Chitosan                                    Esat-6/3e-FL                                                        NA                        Ionic crosslink and coacervation                     311.2±34 nm                         30.6 mV                      Intramuscular Intranasal             Female C57Bl/6 mice                                 NA                            IFN-γ IL-12 IL-10 IL-4               *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Ai *et al* ([@ref41])              2013   Chitosan                                    pHSP65pep                                                           NA                        Coacervation method                                  350 -400 nm                         NA                           Intranasal Intradermal               Female BALB/c mice                                  IgA IgG IgG1 IgG2a            IFN-γ                                *M. bovis*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Verma *et al* ([@ref42])           2013   Chitosan-TPP                                CFP-10 CFP-21                                                                                 Ionotropic gelation                                  250 -300 nm                         41 ±5.29                     NA                                   NA                                                  NA                            IFN-γ IL-4                           NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Caetano *et al* ([@ref43])         2013   Chitosan/Alginate/TPP                       BCG                                                                 NA                        Ionotropic gelation                                  33.865 µm ±5.347                    +10.91 ± 3.55                Intranasal Subcutaneous              Female BALB/c mice                                  IgG IgG 1 IgG2a IgA           NA                                   NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Zhu *et al* ([@ref44])             2007   Chitosan                                    AMM                                                                 IFA                       Precipitation/coacervation method                    5.78 ± 0.65 µm                      32.77 ± 1.51                 Subcutaneous                         Female C57Bl/6 mice                                 IgG1 IgG2a                    IFN-γ IL-4                           NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Bivas-Benita *et al* ([@ref45])    2004   Chitosan                                    DNA vaccine encoding eight HLA-A\*0201-restricted T-cell epitopes   NA                        Complexation-coacervation method                     376±59 nm                           21±4                         Pulmonary Intramuscular              Female HLA-A2 transgenic mice                       NA                            IFN-γ                                NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Dobakhti *et al* ([@ref46])        2009   NA                                          BCG                                                                 Sodium alginate           NA                                                   NA                                  NA                           Subcutaneous                         Female BALB/c mice                                  Total IgG IgG2a IgG1          IFN-γ                                *M. bovis*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Ajdary *et al* ([@ref47])          2007   Sodium alginate                             BCG                                                                 NA                        NA                                                   11.5 μm                             NA                           Subcutaneous Oral                    Female BALB/c mice                                  Total IgG IgG2a IgG1          IFN-γ IL-4                           *M. bovis*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Dobakhti *et al* ([@ref48])        2006   Calcium alginate                            BCG                                                                 NA                        Internal emulsification method                       11 μm                               NA                           Subcutaneous Oral                    Female BALB/c mice                                  Total IgG IgG2a IgG1          NA                                   NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Wilkinson *et al* ([@ref49])       2000   Polystyrene                                 Ag85A, B and C                                                      NA                        NA                                                   2 μm                                NA                           NA                                   NA                                                  NA                            IFN-γ                                NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Yu *et al* ([@ref50])              2012   Fe~3~O~4~-Glu-polyethyleneimine             Ag85A-ESAT-6-IL-21                                                  NA                        NA                                                   NA                                  +36 mV                       Intramuscular Subcutaneous           Male C57BL/6 mice                                   NA                            IFN-γ                                *M. tuberculosis* H37Rv
                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Ballester *et al* ([@ref51])       2011   Pluronic-stabilized polypropylene sulfide   Ag85B                                                               CpG                       Emulsion polymerization and surface functionalized   30 nm                               NA                           Intradermal Pulmonary                Female C57BL/6 mice                                 NA                            IFN-γ TNF-α IL-6 IL-1β IL-17a IL-2   *M. tuberculosis* Erdman strain

Abbreviations: O/W: Oil-in-water single emulsion, W/O/W: Double emulsion/solvent evaporation, MOMP: Major outer-membrane protein, Apa: Alanine-proline antigen, MDP: Muramyl dipeptide, BSA: Bovine serum albumin, AS01B: Composed of MPL and QS21 (saponin molecule), RC-529 adjuvant: A synthetic ω-amin-oalkyl-2-amino-2-deoxy-4-phosphono-²-d-glucopyranoside (AGP) which is structurally related to the major hexaacyl component of MPL adjuvant, FIA: Freund's incomplete adjuvant, ID93: Fusion protein containing *M. tuberculosis* genes Rv3619, Rv1813, Rv3620, and Rv2608, GLA-SE: A mixture of squalene, DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), poloxamer 188, glycerol, and ammonium phosphate buffer, Esat-6/3e-FL: Esat-6 three T cell epitopes (Esat-6/3e) and fms-like tyrosine kinase 3 ligand (FL) genes, pHSP65pep: pECANS plasmid with four epitopes cast in the gene backbone of HSP65, namely ESAT-6~64-76~, Ag85A~124--135~, CFP-10~55--69,~ and Ag85B~141--153~, TPP: Tripolyphosphate, AMM: Ag85B--MPT64~190--198~--Mtb8.4, Fe~3~O~4~-Glu-PEI: Fe~3~O~4~-Glutamic acid-Polyethyleneimine, NA: Not available

So far, just two studies have investigated the application of PLA polymers as vaccine delivery systems for TB subunit vaccines. Data shows that the microencapsulated antigen was highly immunogenic and nasal delivery of the microencapsulated TB antigen generated specific cellular immune responses ([Table 1](#T1){ref-type="table"}).

However, no study on the application of other biodegradable synthetic polymers, poly (alkyl cyano-acrylates), poly (ɛ-caprolactone), or polyphosphates, as TB vaccine delivery systems/adjuvants was found for the present systematic review.

Non-biodegradable synthetic polymers {#sec2-4}
------------------------------------

Our study shows the higher capacity of poloxamer polymers amongst other non-biodegradable synthetic polymers, like polyvinylpyrrolidone and poly (methyl methacrylates), in the induction of protective immunity against *M. tuberculosis*. It has been shown that after pulmonary delivery of the TB antigen with poloxamer polymers, as single adjuvants or combined with other adjuvants; these polymers have good potentials in stimulation of humoral and cell-mediated immune responses. However, no study was found on polyvinylpyrrolidone or poly (methyl methacrylates) to better compare the non-biodegradable synthetic polymers as adjuvants, nano-, or micro-carriers for TB vaccines.

Natural polymers {#sec2-5}
----------------

Studies on albumin, collagen, and gelatin as natural polymers were not found except one on the albumin polymer. It has been reported that albumin polymers can induce antigen-specific mucosal and systemic immune responses. To date, there are no studies on collagen and gelatin as TB vaccine carriers. Ten studies on chitosan/chitin and alginate (natural polysaccharide polymers) were found. Chitosan polymers are widely used as TB vaccine delivery systems/adjuvants. It was shown that chitosan can induce increased levels of antibody and IFN-γ secretion against TB antigens.

Discussion {#sec1-4}
==========

Main prevention strategies against TB are prophylactic and post-exposure vaccination. Prophylactic vaccines may be used either for replacing BCG, like live mycobacterial vaccines, or as a booster for BCG, like subunit vaccines. Post-exposure vaccines are used for elimination of the disease in latently-infected individuals and to prevent disease reactivation ([@ref52]). Ag85A, Ag85B, Ag85C, TB10.4, MPT-64, MPT-83, ESAT-6, CFP-10, Mtb8.4, and hsp65 are among main TB antigens that are used as DNA or subunit vaccines, either alone or as a fusion protein. These antigens could induce specific antibodies and cell-mediated immune responses ([Table 1](#T1){ref-type="table"}). These are mostly expressed in the early phase of infection by the replicating bacteria, however, to induce a broad spectrum of immune responses, antigens expressed in latency phase of non-replicating bacteria are also important, because they are often hidden from the immune system ([@ref53]). This review suggests that ideal vaccination approach against both acute and latent TB infections is using both early and late stage antigens of *M. tuberculosis* (multistage booster vaccines).

TB DNA and subunit vaccines have high safety profiles and have shown promising results in animal models, however, in human clinical trials, they were poor immunogens ([@ref8], [@ref24]). To overcome this problem, polymer-based particles have been used as adjuvant/delivery systems to potentiate the immune responses. Among them, PLGA particles were mostly used for delivery of prophylactic TB vaccines ([Table 1](#T1){ref-type="table"}). The PLGA (50:50) copolymer as compared with the various polymer compositions (like 75:25 and 53:47), was the most frequently used PLGA polymer. The PLGA (75:25) as an intermediate copolymer has more efficient protein release (due to faster degradation) than the PLA homopolymer and more prolonged release profile in comparison with the PLGA (50:50) copolymer ([@ref25]). As presented in [Table 1](#T1){ref-type="table"}, using cationic lipids as adjuvants in combination with PLGA polymers could affect the size, zeta-potential, polydispersity index (PDI), entrapment efficiency, *in vitro* release profile, and also elicit simultaneously humoral and cell-mediated immune responses ([@ref8], [@ref25]). The cationic lipids skew the immune response towards the Th1 branch of immunity and IgG2a production, which is important for immunization against TB. In the presence of cationic lipids, reduction in particle size and PDI, change of zeta potential from negative to positive, and the decrease in antigen entrapment were observed. Similar results have been shown by Wedlock *et al* and Jensen *et al* ([@ref54], [@ref55]). As shown in [Table 1](#T1){ref-type="table"}, encouraging results have been observed after administration of PLGA-based TB vaccines via various routes. Several studies have shown that the PLGA polymer is well-tolerated in the most common injection sites, i.e., subcutaneous and intramuscular spaces ([@ref56]). Due to biocompatibility, adjuvanticity, and prolonged release profile of PLGA particles, mucosal (nasal, oral, and pulmonary) administration of PLGA-based vaccines have shown promising results ([@ref25]).

PLA particles can be built with the same method as PLGA particles and induced robust Th1-type responses (IFN-γ) against TB ([Table 1](#T1){ref-type="table"}). However, the main disadvantages of PLA polymers are the possibility of denaturation of encapsulated protein and also change in immunogenicity of loaded antigens during particle formulation and in the release period ([@ref35]). To preserve the antigens' integrity, antigens could be adsorbed onto the PLA or PLGA particles.

Other biodegradable synthetic polymers, such as poly (ɛ-caprolactone), are also suitable for preparation of vaccine delivery systems ([@ref56]). However, these polymers have not been tried for delivery of TB vaccines.

Non-biodegradable synthetic polymers compared to biodegradable synthetic and natural polymers have been less frequently used as carrier/adjuvant for TB vaccines. However, as discussed in the Todoroff *et al* study, Poloxamer 407 (a non-biodegradable synthetic polymer) combined with a CpG oligonucleotide, induced immune responses against the *M. tuberculosis* antigen (Ag85A) ([Table 1](#T1){ref-type="table"}) ([@ref36]).

It is suggested that natural polymers due to milder preparation process, lower prices, and their adjuvant potential are attractive materials for replacement with biodegradable synthetic polymers ([@ref56]). The protective and immunogenic efficacy of the vaccines based on the natural polymers has been shown in many studies. Yeboah *et al* and Dobakhti *et al* have shown that oral delivery of albumin and alginate microspheres loaded with TB vaccines could induce mucosal and systemic immune responses ([@ref38], [@ref46]). As [Table 1](#T1){ref-type="table"} represents, alginate-based TB vaccines have been administered subcutaneously and orally. According to these studies, alginates may be appropriate for utilization in oral vaccination and will protect encapsulated BCG against degradation in the stomach and induce strong Th1 immune responses against TB ([@ref46]-[@ref48], [@ref56]). Several studies have indicated that chitosan-based vaccines can significantly promote Th1 and CTL immune responses and prevent TB infection ([@ref39]-[@ref45]). According to the different studies shown in [Table 1](#T1){ref-type="table"}, due to antigen depot, efficient uptake by membrane epithelium, and mucoadhesive and adjuvant properties of these biodegradable particulate delivery systems, they are ideal intranasal vaccine delivery systems/adjuvants against TB. As mentioned in [Table 1](#T1){ref-type="table"}, polymer-based TB vaccines have shown promising results in pre-clinical studies and were able to protect animal models against challenge with the virulent *M. tuberculosis* H37Rv strain, however, none of these vaccines entered clinical trials. Due to the results obtained in this study, we are optimistic about introduction of polymer-based TB vaccines to the clinical trial pipeline as potential antigen delivery systems/adjuvants for parenteral and non-parenteral immunization.

Conclusion {#sec1-5}
==========

In summary, the present systematic review reveals that to develop a new TB vaccine, more attention to antigens expressed in early and latency phase of *M. tuberculosis* infection is needed. On the other hand, for improving the weak immunogenicity of these antigens, co-delivery of TB vaccines with polymeric particles could be beneficial in reduction of obstacles against development of new and more efficient TB vaccines. The present study revealed that various polymeric particles could be used as carriers for parenteral and mucosal administration of TB vaccine candidates. Among the polymers reviewed, PLGA and chitosan polymers are the most outstanding ones that show promising results, after subcutaneous and mucosal administration, respectively. Non-biodegradable synthetic polymers in comparison with biodegradable synthetic and natural polymers have been used less frequently. Therefore, further study on this category of polymers is required.
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